COMMUNIQUÉS West-GlobeNewswire

Cronos Group Announces Expansion of GrowCo to Fuel Global Growth
20/06/2024
TORONTO, June 20, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, announced an expansion of Cronos Growing Company (“GrowCo [...]
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
20/06/2024
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene [...]
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
20/06/2024
WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell [...]
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
20/06/2024
Additional presentation will further characterize the potential impact of bezisterim on motor and specific non-motor symptoms of Parkinson’s disease CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., ( [...]
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
20/06/2024
Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening and resistant bacteria SYDNEY, June 20, 2024 (GLOBE NEWSWIRE) -- [...]
Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé
19/06/2024
Les données indiquent des tendances vers une réduction des toxicités et de meilleurs résultats pour les sujets recevant l’association ONIVYDE/5-FU et une thérapie ciblée par anti-IL-1alpha AUSTIN, Texas, 19 juin 2024 ( [...]
Healthcare Integrated Technologies, Inc. Welcomes Dustin Hillis as Chief Strategy Officer
19/06/2024
Knoxville, Tennessee, June 19, 2024 (GLOBE NEWSWIRE) -- Healthcare Integrated Technologies, Inc. (“HiTC”), a leader in developing advanced healthcare technology solutions, is thrilled to announce the appointment of [...]
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
19/06/2024
OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic C ompany’s Growth Nantes, France – June 19, 2024, 6:15pm CET – OSE [...]
OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société
19/06/2024
OSE Immunotherapeutics présente les résultats de l’Assemblée générale 2024 et l’évolution du Conseil d’administration prêt à conduire la stratégie de croissance de la Société Nantes, France – le 19 juin 2024, 18 heures [...]
New Report Tracks Revenue Generated by Allied Healthcare Professionals
19/06/2024
Revenues May Exceed $2 Million Per Year After Staffing Costs DALLAS, June 19, 2024 (GLOBE NEWSWIRE) -- Allied health professionals such as radiology technologists and therapists can generate millions of dollars a year [...]
Rendever and Lenovo Collaborate to Bring Virtual Reality Experiences to Carolina Caring Seniors
19/06/2024
The joint project fuses Rendever’s platform with Lenovo’s ThinkReality VRX headset for an all-in-one VR approach that enhances the quality of life of older adults BOSTON, June 19, 2024 (GLOBE NEWSWIRE) -- Rendever , the [...]
Sharecare announces inducement grants under Nasdaq Listing Rule 5635(c)(4)
19/06/2024
ATLANTA, June 19, 2024 (GLOBE NEWSWIRE) -- Sharecare (NASDAQ: SHCR ), the digital health company that helps people manage all their health in one place, today announced that on June 14, 2024, its Board of Directors (the [...]
Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association
19/06/2024
Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP) Investigators conclude that [...]
Calibre Scientific Acquires DCS, a German Provider of Antibodies, Reagents and Equipment Used in Immunohistochemistry
19/06/2024
LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of DCS Innovative Diagnostik-Systeme GmbH & Co. KG (“DCS” or the “Company”), a German supplier of reagents and [...]
Calibre Scientific fait l’acquisition de DCS, un fournisseur allemand spécialisé dans les anticorps, les réactifs et les équipements utilisés en immunohistochimie
19/06/2024
LOS ANGELES, 19 juin 2024 (GLOBE NEWSWIRE) -- Calibre Scientific a le plaisir d’annoncer l’acquisition de DCS Innovative Diagnostik-Systeme GmbH & Co. KG (« DCS » ou la « Société »), un fournisseur allemand [...]
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
19/06/2024
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
19/06/2024
Patent No. US 11,998,632 B2 (“Patent”) covers Avicanna’s self-emulsifying drug delivery system (“SEDDS”) oral cannabinoid composition and methods of treating neuropathic pain TORONTO, June 19, 2024 (GLOBE NEWSWIRE) -- [...]
Philips completes cancellation of 4.4 million shares
19/06/2024
June 19, 2024 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that it has completed the cancellation of 4,437,164 of its shares. The cancelled shares were acquired as part of the [...]
Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
19/06/2024
Laboratory of Prof. Andrea Alimonti at IOR (Institute of Oncology Research, Bellinzona, Switzerland) and Macomics to bring together expertise on myeloid-derived suppressor cells in prostate cancer mouse model systems [...]

Pages